Aktis Oncology (NASDAQ:AKTS) Stock Price Up 8.8% – Still a Buy?

Aktis Oncology (NASDAQ:AKTS)’s share price traded up 8.8% during trading on Tuesday . The company traded as high as $33.15 and last traded at $32.7560. 134,837 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 322,742 shares. The stock had previously closed at $30.11.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on AKTS shares. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. HC Wainwright boosted their target price on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Raymond James Financial began coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. Finally, William Blair started coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.00.

Aktis Oncology Price Performance

The firm has a 50 day moving average price of $21.12.

Aktis Oncology (NASDAQ:AKTS) last issued its earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The company had revenue of $1.87 million during the quarter. As a group, analysts forecast that Aktis Oncology will post -1.62 EPS for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.